Empiric Antibiotic Selection for Uncomplicated Nonpurulent Skin Infections
For uncomplicated nonpurulent cellulitis, β-lactam monotherapy with an oral agent active against streptococci (eg, cephalexin) is recommended because typical cellulitis pathogens are predominantly streptococci. [1] Trimethoprim-sulfamethoxazole (TMP-SMX) is not reliably active against β-hemolytic streptococci, so it does not provide dependable coverage when infection is nonpurulent and MRSA coverage is not indicated. [1]
Expected Pathogens in Uncomplicated Nonpurulent Cellulitis
Nonpurulent cellulitis typically reflects infection caused by β-hemolytic streptococci, so antibiotic selection should prioritize streptococcal activity. [1] MRSA is described as an uncommon cause of typical (nonpurulent) cellulitis, so routine empiric MRSA coverage is generally unnecessary in uncomplicated cases. [1]
Coverage Differences Between Cephalexin and TMP-SMX
Cephalexin is active against streptococci and is listed as a suitable oral option for typical cellulitis. [1] The activity of TMP-SMX (and doxycycline) against β-hemolytic streptococci is not known. [1] Because of this lack of reliable streptococcal activity, TMP-SMX provides less dependable pathogen coverage for nonpurulent cellulitis than cephalexin. [1]
Evidence from Clinical Trials
A randomized, double-blind trial enrolled patients with cellulitis without abscesses who received cephalexin and were randomized to add TMP-SMX or placebo. [2] Treatment success rates were similar between groups (cephalexin plus TMP-SMX: 85% cured versus cephalexin alone: 82% cured), with no statistically significant difference. [2] This trial result supports that adding TMP-SMX to cephalexin does not improve outcomes for pure nonpurulent cellulitis. [1][2]
When TMP-SMX Is Considered Instead of Cephalexin
MRSA-directed therapy is recommended when clinical features suggest purulence/abscess or when specific risk factors are present for MRSA in the setting of cellulitis. [1] When MRSA is a concern and oral therapy is needed, TMP-SMX is listed as an oral option for MRSA coverage in relevant SSTI scenarios. [1]
Clinical Implication for “Uncomplicated Skin Infections”
If the clinical presentation is consistent with uncomplicated nonpurulent cellulitis, cephalexin is favored because it provides dependable streptococcal coverage while MRSA-directed therapy is often unnecessary. [1] If the presentation is purulent or strongly suggests MRSA, TMP-SMX may be appropriate as MRSA-directed therapy, with coverage decisions based on the presence of purulence and other MRSA risk features. [1]